Aprogen Biologics Inc. (KRX: 003060)

Aprogen Biologics Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	23,635	10,053	23,609	35,074	64,796	30,297
Short-Term Investments	-	-	390	75,000	140,000	40,000
Trading Asset Securities	-	-	75,075	14,861	279.12	22,213
Cash & Short-Term Investments	23,635	10,053	99,074	124,935	205,075	92,510
Cash Growth	-75.42%	-89.85%	-20.70%	-39.08%	121.68%	139.33%
Accounts Receivable	12,532	14,807	17,769	12,825	12,620	13,144
Other Receivables	2,101	1,828	4,256	8,259	5,185	2,931
Receivables	30,672	23,373	82,060	215,755	119,490	93,075
Inventory	54,936	48,128	52,313	10,420	10,040	8,758
Prepaid Expenses	-	2,490	558.14	10.67	14	120.04
Other Current Assets	1,276	812.78	6,604	2,354	1,904	1,128
Total Current Assets	110,519	84,857	240,608	353,474	336,523	195,591
Property, Plant & Equipment	315,042	318,212	323,773	18,857	19,801	45,907
Long-Term Investments	137,520	137,647	57,793	84,232	104,099	91,967
Other Intangible Assets	5,720	6,241	6,458	2,796	3,157	3,235
Long-Term Accounts Receivable	-	-	-	20,577	-	-0
Long-Term Deferred Tax Assets	-	-	662.84	755.7	658.89	793.39
Long-Term Deferred Charges	-	-	-	-	478	274.3
Other Long-Term Assets	3,720	3,793	10,099	9,229	31,082	27,516
Total Assets	610,829	589,397	684,140	614,621	615,309	365,283
Accounts Payable	3,119	1,333	3,809	652.59	808.22	535.88
Accrued Expenses	2,823	3,747	4,968	1,201	720.94	659.5
Short-Term Debt	74,398	90,026	134,263	2,162	2,621	3,446
Current Portion of Long-Term Debt	41,029	39,335	-	-	-	-
Current Portion of Leases	-	1,360	345.5	199.49	185.77	188.65
Current Income Taxes Payable	-	-	4.18	273.93	461.17	-
Current Unearned Revenue	-	-	-	119.99	119.99	188.22
Other Current Liabilities	34,149	22,138	17,716	4,840	3,758	5,796
Total Current Liabilities	155,518	157,938	161,106	9,449	8,675	10,815
Long-Term Debt	32,000	32,000	-	-	-	-
Long-Term Leases	16,865	18,277	129.06	120	163.92	228.02
Long-Term Deferred Tax Liabilities	2,932	2,932	3,108	1,093	927.58	-
Other Long-Term Liabilities	2,028	1,827	1,823	1,178	998.31	399.9
Total Liabilities	218,741	220,705	173,730	17,440	16,953	17,646
Common Stock	66,164	332,877	292,877	199,288	199,288	120,829
Additional Paid-In Capital	678,211	358,030	335,850	327,715	327,715	165,662
Retained Earnings	-163,548	-133,310	-8,085	-21,115	-30,114	-41,771
Treasury Stock	-4,485	-4,463	-41.27	-41.27	-41.27	-41.27
Comprensive Income & Other	-184,255	-184,443	-194,079	2,092	8,547	1,664
Total Common Equity	392,088	368,691	426,521	507,939	505,395	246,343
Minority Interest	-	-	83,890	89,242	92,961	101,294
Shareholders' Equity	392,088	368,691	510,411	597,181	598,356	347,637
Total Liabilities & Equity	610,829	589,397	684,140	614,621	615,309	365,283
Total Debt	164,292	180,997	134,738	2,481	2,971	3,863
Net Cash (Debt)	-140,657	-170,944	-35,664	122,454	202,104	88,647
Net Cash Growth	-	-	-	-39.41%	127.99%	13677.82%
Net Cash Per Share	-2121.05	-2709.80	-882.32	3072.33	6364.69	5420.55
Filing Date Shares Outstanding	131.49	65.75	58.57	39.86	39.86	24.17
Total Common Shares Outstanding	131.49	65.75	58.57	39.86	39.86	24.17
Working Capital	-44,999	-73,081	79,502	344,025	327,848	184,776
Book Value Per Share	2981.80	5607.21	7281.63	12744.01	12680.19	10194.07
Tangible Book Value	386,367	362,451	420,063	505,142	502,238	243,108
Tangible Book Value Per Share	2938.30	5512.30	7171.38	12673.85	12600.98	10060.22
Land	25,156	25,156	28,315	9,313	8,463	8,463
Buildings	82,028	97,507	101,378	9,647	10,460	10,460
Machinery	73,665	118,620	145,738	10,258	9,494	9,231
Construction In Progress	112,251	108,996	90,433	-	392	-

Source: S&P Capital IQ. Standard template. Financial Sources.